Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3571-3581

  Tran, Melissa A ^a   Smith, Charles D ^e   Kester, Mark ^a,c   Robertson, Gavin P ^a,b,c,d  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Department of Pathology ^*

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d Foreman Foundation for Melanoma Research   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CERAMIDE; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; NANOPARTICLE; PROTEIN KINASE B; PYRIDINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; BREAST TUMOR; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CERAMIDES; DRUG SYNERGISM; HUMANS; LIPOSOMES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 47949086963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4881     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Chang F, Steelman LS, Shelton JG, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway [review]. Int J Oncol 2003; 22:469-80.
3. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24: 7455 - 64.
4. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
5. Mercer KE, Pritchard CA Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
6. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
8. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocyte lesions. J Invest Dermatol 2003;121:1160-2.
9. Miller CJ, Cheung M, Sharma A, et al. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004; 123:990-2.
10. Maemura M, linoY, Koibuchi Y, YokoeT, MorishitaY. Mitogen-activated protein kinase cascade in breast cancer. Oncology 1999;57 Suppl 2:37-44.
11. Sharma A.Trivedi NR, Zimmerman MA,Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21.
12. Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by in-activation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004:23:6031 -9.
13. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M.Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202
14. Wilhelm SM, Carter C, dang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 2004;64:7099-109.
15. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006:5: 835-44.
16. EisenT, AhmadT, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006:95:581 -6.
17. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006:12:7271 -8.
18. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006:66: 3963-6.
19. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007;67:3626-36.
20. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 2003;228:995-1003
21. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004:64:7002-10
22. StoverTC, Sharma A, Robertson GP. Kester M Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005:11:3465 - 74.
23. Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol ExpTher 2003:307 468-75.
24. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004:64 4394-9.
25. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998; 60:643-65.
26. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994:269:3125-8.
27. Spiegel S. Merrill AH. Jr. Sphingolipid metabolism and cell growth regulation. FASEB J 1996:10 1388-97.
28. Merrill AH, Jr., Schmelz EM, Dillehay DL. et al Sphingolipids - the enigmatic lipid class biochemistry, physiology, and pathophysiology Toxicol Appl Pharmacol 1997;142:208-25.
29. Shabbits JA, Mayer LD, Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 2003:1612:98-106
30. Shabbits JA, Mayer LD. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res 2003,23:3663-9
31. Mehta S, Blackinton D. Omar I, et al Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 2000;46: 85-92.
32. Han WS, Yoo JY, Youn SW, et al. Effects of C2-ceramide on the Malme-3M melanoma cell line. J Dermatol Sci 2002;30:10-9.
33. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881 - 90.
34. ChouTC,Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
35. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94.
36. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol ExpTher 2006;319:1070-80.
37. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44.
38. 2-terminal kinase pathways. Mol Cancer Ther 2006;5:2378-87.
39. Siu LL, Awada A.Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51.
40. Bedogni B, O'Neill MS, Welford SM, et al. Topical treatment with inhibitors of the phosphatidylinositol 3́-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004; 64:2552-60.
41. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-300.
42. Ratain MJ, EisenT, StadlerWM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
43. Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73.
44. Richly H, Kupsch P, Passage K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42:650-1.
45. PlastarasJP, KimSH, LiuYY,etal. Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007:67: 9443-54.
46. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002:62:5381 -5.
47. Zhou H, Summers SA, Birnbaum MJ, Pittman RN. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J Biol Chem 1998:273:16568-75.
48. 2 induce caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem 2002;277: 42943-52.
49. Kim DS, Kim SY, Moon SJ, et al. Ceramide inhibits cell proliferation through Akt/PKB inactivation and decreases melanin synthesis in Mel-Ab cells. Pigment Cell Res 2001;14:110-5.
50. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 2008;68:5-8.